Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
To access this article, please choose from the options below
The PROVE IT-TIMI 22 trial was supported by Bristol-Myers Squibb, Princeton, NJ. Drs Morrow and Sabatine are supported in part by National Institutes of Health grant U01 HL083-1341. This work was also supported in part by grants from the National Institutes of Health (HL57506 and HL60942 to Dr Simon). Dr Pradhan is supported by funding from the National Institutes of Health (HL082740). Dr Libby is supported by research funds from the Leducq Foundation (Paris, France), the Doris Duke Foundation (New York, NY), and the Donald W. Reynolds Foundation (Las Vegas, NV).
PII: S0002-8703(07)00704-1
doi:10.1016/j.ahj.2007.08.018
© 2008 Published by Elsevier Inc.
